The EBOVAC2 project is one of 8 projects funded under IMI Ebola+ programme that was launched in response to the Ebola virus disease outbreak. The project aims to assess the safety and efficacy of a novel prime boost preventive vaccine regimen against Ebola Virus Disease (EVD).

To expedite the development of the vaccine regimen, Phase 2 and Phase 3 trials will be carried out in parallel and therefore coordinated by two separate teams within EBOVAC1 (Phase 1 trials and Phase 2B large scale safety and immunogenicity study) and EBOVAC2 (Phase 2 trial) projects. Find out more about Phase 2.

Between them, the EBOVAC projects will assess, through phase 1, 2 trials and Phase 2B study in Europe and Africa, the safety and tolerability of the vaccine regimen in response to the urgent public health need raised by the Ebola epidemic.

Currently, there are no proven therapies to treat Ebola or vaccines to prevent infection/disease. Thus, in view of the current Ebola epidemic, on September 5th 2014, the World Health Organisation identified the progression of Ebola vaccine candidates currently in development as an urgent public health need. Several candidate vaccines are available. No vaccines have been approved for human use to prevent or treat Ebola, although several are promising in animal models (such as the vaccine regimen being proposed in the EBOVAC programme). In view of the urgency of these outbreaks, the international community is seeking to find ways to accelerate the evaluation and use of these products.

Based on the WHO recommendations, EBOVAC2 will provide data to assess the safety, immunogenicity and efficacy of a novel candidate vaccine regimen to prevent Ebola virus disease (EVD).

Find out more about the EBOVAC1 trials:

Phase 1:
Trial countries: UK and selected African countries currently unaffected by Ebola

Phase 2B large scale safety and immunogenicity study 

More information coming soon...


  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA

    Press release and more information

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

  • 29 February 2016

    The first subject was randomized on 10 December 2016 at Makerere University in Uganda.

  • 29 February 2016

    The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research